Industry Wire 263

April 11, 2025 Viktor Zarev 0 min read
  1. FDA shifts away from animal testing for drug development. 
  2. Prospect’s beleaguered Penn. hospitals get last-minute lifeline. 
  3. Medicare Advantage contracts squeeze rural hospitals.
  4. ‘Chaos and questions’ at U.S. health agencies. 
  5. NIH reverses conference attendance ban for scientists. 
  6. Healthcare welcomes pause to tariff turmoil. 
  7. Novartis to spend $23B on U.S. drug plants.
  8. Medicare paid Medicare Advantage $38B for non-Medicare services.
  9. Employers are willing to pay for anti-obesity meds.
  10. One-third of maternal deaths happen long after delivery.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Structural Heart November 3, 2025

Abbott’s Tendyne TMVR System Works Even in the Sickest MR Patients November 3, 2025

New research presented at TCT 2025 suggests that Abbott’s FDA-approved Tendyne TMVR system leads to significantly better health outcomes in patients with severe mitral annular calcification who were previously considered untreatable. The SUMMIT-MAC trial enrolled 103 patients with severe MAC and found that the challenging patient population showed strong outcomes despite extreme pathology… However, patients […]

Cardiology October 30, 2025

The Top Trends of TCT 2025 October 30, 2025

This year marked the 37th Annual Transcatheter Cardiovascular Therapeutics conference, and while the core of the conference is still catheter-based heart therapies, this year’s research studies and device demonstrations made it clearer than ever that cardiac medtech continues to push the boundaries of what can be done with a catheter. Structural Heart is King – […]

Cardiovascular Disease October 27, 2025

Genetic Risk Scores Improve CAD Detection October 27, 2025

Coronary artery disease risk assessment might soon rely on genetic testing, following a UK Biobank analysis that suggests adding a CAD multi-gene risk score to conventional biomarkers significantly improves disease prediction and patient identification. Examining genetic profiles, researchers followed 353k UK Biobank participants without baseline CAD for 11 years on average, and compared the predictive […]